Next earnings date: 14 Aug 2025
AIM ImmunoTech Inc. – AMEX:AIM
AIM ImmunoTech stock price today
AIM ImmunoTech stock price monthly change
AIM ImmunoTech stock price quarterly change
AIM ImmunoTech stock price yearly change
AIM ImmunoTech key metrics
Market Cap | 12.18M |
Enterprise value | N/A |
P/E | -1 |
EV/Sales | -71.74 |
EV/EBITDA | 0.47 |
Price/Sales | 143.87 |
Price/Book | 0.45 |
PEG ratio | -0.09 |
EPS | -0.64 |
Revenue | 193K |
EBITDA | -32.15M |
Income | -31.11M |
Revenue Q/Q | -18.36% |
Revenue Y/Y | 23.71% |
Profit margin | -15598.51% |
Oper. margin | -16278.36% |
Gross margin | -140.3% |
EBIT margin | -16278.36% |
EBITDA margin | -16662.69% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAIM ImmunoTech stock price history
AIM ImmunoTech stock forecast
AIM ImmunoTech financial statements
| Jun 2023 | 42K | -4.90M | -11688.1% |
|---|---|---|---|
| Sep 2023 | 46K | -7.81M | -16991.3% |
| Dec 2023 | 65K | -12.57M | -19347.69% |
| Mar 2024 | 40K | -5.81M | -14542.5% |
| Dec 2023 | 65K | -12.57M | -19347.69% |
|---|---|---|---|
| Mar 2024 | 40K | -5.81M | -14542.5% |
| Oct 2025 | 47.24K | -5.44M | -11515.01% |
| Dec 2025 | 100K | -5.44M | -5440.38% |
Analysts Price target
Financials & Ratios estimates
| 2024-05-16 | -0.12 | -0.12 |
|---|---|---|
| 2024-11-14 | -0.1 | -0.06 |
| Jun 2023 | 33617000 | 3.48M | 10.36% |
|---|---|---|---|
| Sep 2023 | 27861000 | 5.25M | 18.88% |
| Dec 2023 | 19417816 | 9.18M | 47.3% |
| Mar 2024 | 16189000 | 11.36M | 70.19% |
| Jun 2023 | -2.15M | -204K | 5K |
|---|---|---|---|
| Sep 2023 | -5.67M | -336K | 233K |
| Dec 2023 | -9.75M | -214K | 147K |
| Mar 2024 | -4.81M | -158K | 2.82M |
AIM ImmunoTech alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 26 |
| Jun 2024 | 26 |
| Jul 2024 | 26 |
AIM ImmunoTech other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 243009 | 0 |
| May 2024 | 92594 | 0 |
| Sep 2024 | 25000 | 0 |
| Nov 2024 | 227063 | 0 |
| Dec 2024 | 33839 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 22,727 | $0.21 | $4,682 | ||
Purchase | APPELROUTH STEWART director | Common Stock | 11,111 | $0.21 | $2,356 | ||
Purchase | APPELROUTH STEWART director | Common Stock | 1 | $0.21 | $0 | ||
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 85,000 | $0.2 | $16,915 | ||
Purchase | APPELROUTH STEWART director | Common Stock | 81,953 | $0.19 | $15,817 | ||
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 60,110 | $0.18 | $11,000 | ||
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 5,000 | $0.3 | $1,515 | ||
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 20,000 | $0.31 | $6,160 | ||
Purchase | EQUELS THOMAS K director, officer: CEO & Presid.. | Common Stock | 61,729 | $0.41 | $25,000 | ||
Purchase | RODINO PETER W III officer: COO, Sec.. | Common Stock | 30,865 | $0.41 | $12,500 |
| Patent |
|---|
Application Filling date: 20 Dec 2019 Issue date: 31 Mar 2022 |
Application Filling date: 25 Nov 2019 Issue date: 3 Mar 2022 |
Application Filling date: 18 Feb 2021 Issue date: 1 Jul 2021 |
Application Filling date: 9 Aug 2019 Issue date: 25 Jun 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 16 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 2 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 15 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 15 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Thomas K. Equels Esq., J.D., M.S. (1953) Executive Vice Chairman, Chief Executive Officer & Pres | $1,520,000 |
| Mr. Peter W. Rodino III, Esq., J.D. (1951) Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec. | $681,860 |
| Ms. Ellen M. Lintal (1959) Chief Financial Officer & Chief Accounting Officer | $441,990 |
-
What's the price of AIM ImmunoTech stock today?
One share of AIM ImmunoTech stock can currently be purchased for approximately $2.48.
-
When is AIM ImmunoTech's next earnings date?
AIM ImmunoTech Inc. is estimated to report earnings on Thursday, 14 Aug 2025.
-
Does AIM ImmunoTech pay dividends?
No, AIM ImmunoTech does not pay dividends.
-
How much money does AIM ImmunoTech make?
AIM ImmunoTech has a market capitalization of 12.18M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 43.26% to 202K US dollars. AIM ImmunoTech made a loss 28.96M US dollars in net income (profit) last year or -$0.06 on an earnings per share basis.
-
What is AIM ImmunoTech's stock symbol?
AIM ImmunoTech Inc. is traded on the AMEX under the ticker symbol "AIM".
-
What is AIM ImmunoTech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AIM ImmunoTech?
Shares of AIM ImmunoTech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AIM ImmunoTech's key executives?
AIM ImmunoTech's management team includes the following people:
- Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, Chief Executive Officer & Pres(age: 72, pay: $1,520,000)
- Mr. Peter W. Rodino III, Esq., J.D. Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.(age: 74, pay: $681,860)
- Ms. Ellen M. Lintal Chief Financial Officer & Chief Accounting Officer(age: 66, pay: $441,990)
-
How many employees does AIM ImmunoTech have?
As Jul 2024, AIM ImmunoTech employs 26 workers, which is 18% more then previous quarter.
-
When AIM ImmunoTech went public?
AIM ImmunoTech Inc. is publicly traded company for more then 29 years since IPO on 12 Jul 1996.
-
What is AIM ImmunoTech's official website?
The official website for AIM ImmunoTech is aimimmuno.com.
-
Where are AIM ImmunoTech's headquarters?
AIM ImmunoTech is headquartered at 2117 SW Highway 484, Ocala, FL.
-
How can i contact AIM ImmunoTech?
AIM ImmunoTech's mailing address is 2117 SW Highway 484, Ocala, FL and company can be reached via phone at +352 44 87 79 7.
AIM ImmunoTech company profile:
AIM ImmunoTech Inc.
aimimmuno.comAMEX
26
Biotechnology
Healthcare
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Ocala, FL 34473
CIK: 0000946644
ISIN: US00901B1052
CUSIP: 00901B105
